183 related articles for article (PubMed ID: 23896094)
1. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.
Tsai HT; Penson DF; Makambi KH; Lynch JH; Van Den Eeden SK; Potosky AL
Urology; 2013 Aug; 82(2):327-33. PubMed ID: 23896094
[TBL] [Abstract][Full Text] [Related]
2. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
4. [Risks of diabetes mellitus and impaired glucose tolerance induced by intermittent versus continuous androgen-deprivation therapy for advanced prostate cancer].
Zeng S; Li ZP; Li W; Pu WZ; Liu P; Ma ZF
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):598-602. PubMed ID: 29723451
[TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
[TBL] [Abstract][Full Text] [Related]
6. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
Magnan S; Zarychanski R; Pilote L; Bernier L; Shemilt M; Vigneault E; Fradet V; Turgeon AF
JAMA Oncol; 2015 Dec; 1(9):1261-9. PubMed ID: 26378418
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Yokomizo A; Koga H; Ito K; Takezawa Y; Komiyama M; Nishimura K; Yonese J; Hashine K; Masumori N; Arai G; Saito S; Shinohara M; Shimizu N; Yamauchi A; Satoh T; Tochigi T; Kobayashi M; Fujimoto H; Kakimoto KI; Fukui I; Tsukamoto T; Nozaki M; Karasawa K; Hasumi M; Ohtani M; Ishiyama H; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Naito S; Yamanaka H;
Cancer Med; 2021 May; 10(10):3240-3248. PubMed ID: 33932114
[TBL] [Abstract][Full Text] [Related]
8. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
9. Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.
Parikh RA; Pascal LE; Davies BJ; Wang Z
Asian J Androl; 2014; 16(4):505-10. PubMed ID: 24759577
[TBL] [Abstract][Full Text] [Related]
10. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
11. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
12. Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach.
Bonfill X; Arevalo-Rodriguez I; Martínez García L; Quintana MJ; Buitrago-Garcia D; Lobos Urbina D; Cordero JA
Cancer Manag Res; 2018; 10():2357-2367. PubMed ID: 30122985
[TBL] [Abstract][Full Text] [Related]
13. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.
Botrel TE; Clark O; dos Reis RB; Pompeo AC; Ferreira U; Sadi MV; Bretas FF
BMC Urol; 2014 Jan; 14():9. PubMed ID: 24460605
[TBL] [Abstract][Full Text] [Related]
14. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
15. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
Eggener S
Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
[TBL] [Abstract][Full Text] [Related]
16. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086
[TBL] [Abstract][Full Text] [Related]
17. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
18. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer.
Klotz L
Curr Urol Rep; 2013 Jun; 14(3):159-67. PubMed ID: 23700095
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.
Brungs D; Chen J; Masson P; Epstein RJ
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):105-11. PubMed ID: 24686773
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
